The European Commission Approves the Merger of Mylan and Upjohn with Conditions
Shots:
- The EC has approved the Viatris merger (a merger b/w Upjohn and Mylan) under EU merger regulations but the decision is conditional on the divestment of Mylan's certain generic therapies
- EC ensures that the merger does not harm competition and preserves the competitive access to certain genericized therapies for national health services and the citizens of EU. The EC has investigated the vertical relationships b/w the companies concerning API- out-licensing the supply of genericized therapies
- Mylan and Upjohn overlap in multiple therapeutic areas such as CV- Genito-urinary- musculoskeletal- CNS and sensory organ treatments- but no competition concerns arise for most of the products. The concern was found for 36 molecules in certain EU countries- requiring Mylan to offload those therapies
Click here to read full press release/ article | Ref: European Commission | Image: Pharmabiz
Related News: Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com